SEC Tracker
Get the app

Biomerica BMRA

Biomerica reports fiscal Q1 2027 financials

Form
10-Q
Filed
Importance
Notable
  1. Cash and cash equivalents increased to $2.7M as of Aug 31, 2026
  2. Net loss of $1.2M for the three months ended Aug 31, 2026
  3. Shareholders equity rose to $3.6M as of Aug 31, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Biomerica files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025
  2. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  3. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  4. Vyome Holdings HIND public float $6M, Jun 30, 2025
  5. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025